急性B型主动脉壁内血肿腔内治疗与药物治疗的五年结果:重建时间-事件数据的Meta分析
该系统综述与Meta分析纳入8项观察性研究共1015例急性B型主动脉壁内血肿患者(TEVAR组440例,药物治疗组575例),中位随访5.1年。与单纯药物治疗相比,TEVAR与较低的全因死亡风险(HR 0.44,95%CI 0.30-0.65,p<.001;GRADE证据确定性低)、较低的主动脉相关死亡风险(HR 0.04,95%CI 0.01-0.31,p=.002;GRADE证据确定性低)及更长的限制性平均生存时间(TEVAR总体延长201天,p<.001)相关。作者认为TEVAR可能与较低的全因及主动脉相关死亡风险相关,但现有数据不足以得出稳健的临床结论,需要大样本、更长随访的随机对照试验来阐明该问题。
要点
- 急性B型主动脉壁内血肿中,TEVAR组全因死亡风险低于药物治疗组(HR 0.44,95%CI 0.30-0.65)。
- TEVAR组主动脉相关死亡风险低于药物治疗组(HR 0.04,95%CI 0.01-0.31)。
- TEVAR组限制性平均生存时间总体较药物治疗组延长201天(p<.001)。
核心结论
- 在急性B型主动脉壁内血肿患者中,胸主动脉腔内修复(TEVAR)可能与较低的全因死亡和主动脉相关死亡风险相关,但现有数据不足以得出稳健的临床结论。
- 需要大样本、更长随访的随机对照试验来阐明该问题。
研究设计与样本
- 系统综述与重建时间-事件数据的汇总Meta分析,遵循PRISMA报告规范,方案在PROSPERO注册(CRD42023456222)。
- 检索PubMed/MEDLINE、EMBASE、CENTRAL/CCTR中截至2023年7月发表的符合纳入标准的文章。
- 纳入8项观察性研究,共1015例患者(TEVAR组440例,药物治疗组575例),汇总队列中位随访5.1年。
- 分析总体生存(全因死亡)、主动脉相关死亡和限制性平均生存时间,并用GRADE工具评估证据确定性。
主要发现
- 与单纯药物治疗相比,TEVAR组全因死亡风险 statistically significantly 降低(HR 0.44,95%CI 0.30-0.65;p<.001;GRADE证据确定性低)。
- TEVAR组主动脉相关死亡风险低于药物治疗组(HR 0.04,95%CI 0.01-0.31;p=.002;GRADE证据确定性低)。
- TEVAR组限制性平均生存时间总体较药物治疗组延长201天(p<.001)。
关键数值与推荐
- 全因死亡:TEVAR组 vs 药物治疗组 HR 0.44(95%CI 0.30-0.65;p<.001;GRADE证据确定性低)。
- 主动脉相关死亡:TEVAR组 vs 药物治疗组 HR 0.04(95%CI 0.01-0.31;p=.002;GRADE证据确定性低)。
- 限制性平均生存时间:TEVAR组总体较药物治疗组延长201天(p<.001)。
临床怎么用
- 原文结论指出TEVAR可能与较低的全因及主动脉相关死亡风险相关,但现有数据不足以得出稳健的临床结论。
- 原文建议需要大样本、更长随访的随机对照试验来阐明该问题。
局限性
- 所有纳入研究均为观察性研究。
- 全因死亡和主动脉相关死亡的GRADE证据确定性均为低。
- 原文结论指出现有数据不足以得出稳健的临床结论。
- 原文指出需要大样本、更长随访的随机对照试验来阐明该问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate outcomes in the follow up of thoracic endovascular aortic repair (TEVAR) vs. medical therapy in patients with acute type B aortic intramural haematoma (IMH). DATA SOURCES: The following sources were searched for articles meeting the inclusion criteria and published by July 2023: PubMed/MEDLINE, EMBASE, CENTRAL/CCTR (Cochrane Controlled Trials Register). REVIEW METHODS: This systematic review with pooled meta-analysis of time to event data followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines, and its protocol was registered on the public platform PROSPERO (CRD42023456222). The following were analysed: overall survival (all cause mortality), aortic related mortality, and restricted mean survival time. Certainty of evidence was evaluated through the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) tool. RESULTS: Eight studies met the eligibility criteria, including 1 015 patients (440 in the TEVAR group and 575 in the medical therapy group). All studies were observational, and the pooled cohort had a median follow up of 5.1 years. Compared with patients who received medical therapy alone, those who underwent TEVAR had a statistically significantly lower risk of all cause death (HR 0.44, 95% CI 0.30 - 0.65; p < .001; GRADE certainty: low), lower risk of aortic related death (HR 0.04, 95% CI 0.01 - 0.31; p = .002; GRADE certainty: low) and lifetime gain (restricted mean survival time was overall 201 days longer with TEVAR; p < .001). CONCLUSION: Thoracic endovascular aortic repair may be associated with lower risk of all cause and aortic related death compared with medical therapy in patients with acute type B IMH; however, the underlying data are not strong enough to draw robust clinical conclusions. Randomised controlled trials with large sample sizes and longer follow up are warranted to elucidate this question.
引用
- Sá MP, Jacquemyn X, Tasoudis P, et al. Five Year Results of Endovascular versus Medical Therapy in Acute Type B Aortic Intramural Haematoma: Meta-Analysis of Reconstructed Time to Event Data. Eur J Vasc Endovasc Surg. 2023. PMID: 38145870. doi:10.1016/j.ejvs.2023.12.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。